Author: Zacks Small Cap Research

1313233343541330 / 408 POSTS
By Steven Ralston, CFATSX:WML.VExecutive Summary• Management’s focus is migrating from the acquisition of lithium concessions to the development of its portfolio of lithium brine properties o The 2018 evaluation program is targeting the properties at ...
By David Bautz, PhDNASDAQ:MNOVAdditional Positive Data Presented for MN-166 in MSOn February 1, 2018, MediciNova, Inc. (NASDAQ:MNOV) announced the presentation of additional positive data from the SPRINT-MS clinical trial of MN-166 (ibudilast) in pat ...
By John Vandermosten, CFANASDAQ:CRMENote: This is an abbreviated summary of our full initiation report which is available on our website scr.zacks.comWe are initiating coverage of Cardiome Pharma Corp. (NASDAQ:CRME) with a USD$4.00 price target based ...
By David Bautz, PhDNASDAQ:MTFBMotif Bio Plc (NASDAQ:MTFB) is a biopharmaceutical company focused on the development of antibiotic compounds for difficult to treat bacterial infections. The company’s lead asset, iclaprim, is a novel diaminopyrimidine ...
By Lisa ThompsonNASDAQ:OIIMO2Micro (NASDAQ:OIIM) reported Q4 2017 revenues of $15.2 million, within the range of guidance but slightly below the midpoint. This was down 4% from last year and broke the company’s string of five straight quarters of rev ...
By David Bautz, PhDTSX:ATE.VAntibe Therapeutics Inc. (TSX:ATE.V) is a Canadian biotechnology company developing treatments for pain, inflammation, and regenerative medicine. The company’s lead compound, ATB-346, is an improved non-steroidal anti-infl ...
By Anita Dushyanth, PhDNASDAQ:PULMPulmatrix (NASDAQ:PULM) management filed a Clinical Trial Application (CTA) in 2H 2017 in the EU to support a Phase 1/1b trial in healthy volunteers and asthmatics, which is anticipated to commence in 1H 2018.  The ...
NYSE:HEBWith the stock up 50% over the past 3 months, we believe HEB (NYSE:HEB) is starting to look like an attractive investment.  Since our prior report (November 14, 2017), Hemispherx has made some progress in their Ampligen product development cy ...
By David Bautz, PhDNASDAQ:VKTXBusiness UpdateViking Therapeutics, Inc. (NASDAQ:VKTX) is currently testing VK2809, the company’s thyroid hormone receptor beta (TRβ) agonist, in a Phase 2 clinical trial in patients with hypercholesterolemia and fatty l ...
OTC:GBTCSince its successful ICO (Initial Coin Offering) which closed September 2017, the recently re-branded SOCIAL, has completed its transformation from Nexus to a blockchain and cryptocurrency leader and is well on its way to executing its expans ...
1313233343541330 / 408 POSTS